A Phase 3 interventional study of Filgotinib and PTM filgotinib in Ulcerative Colitis, sponsored by Gilead Sciences. Completed at 343 sites in 40 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-04-21.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 615 studies in Colitis, Ulcerative with a site in United States — 116 open to participants now, 167 under way, 34 of them phase 3. Colitis, Ulcerative · United States.
Among the 615 studies in Colitis, Ulcerative with a site in United States, this one is the 10th largest by enrollment of the 499 interventional ones that give a count, is one of 27 that started in 2016, is one of 116 in phase 3, and was the 266th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →116 of the 615 studies in Colitis, Ulcerative with a site in United States are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States
Ages 16–80
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Sites in United States
Ages 18–85
University of Minnesota · Sites in United States
Ages 18+
Muhammad N Aslam, MD · Sites in United States
Ages 18–80
Vanda Pharmaceuticals · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
615 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 87 · Phase 2 173 · Phase 3 132 · Phase 4 33
First in 1995; this study’s year is marked. 27 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,351 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 76 across the 499 interventional studies, 198 across the 113 observational. Of the 407 that completed or were terminated, 192 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
332 of 615 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Gilead Sciences has 7 studies filed under Colitis, Ulcerative — fewer than ten, so there is no comparison to draw.
55 of the studies in Colitis, Ulcerative with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06589986Phase 3Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | 2027-01-30 |
| NCT06260163Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis | 2027-02-10 |
| NCT04624230Phase 3PfizerEvaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis | 2027-03-17 |
| NCT03006068Phase 3AbbVieA Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | 2027-07 |
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
Add all 55 to your calendar (.ics) → With an account.
Among the 615 studies in Colitis, Ulcerative with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objectives of this study are to evaluate the efficacy of filgotinib in the induction and maintenance treatment of moderately to severely active ulcerative colitis (UC) in participants who are biologic-naive and biologic-experienced.
Participants who complete the study, or met protocol specified efficacy discontinuation criteria will have the option to enter a separate, long-term extension (LTE) study (Gilead Study GS-US-418-3899: NCT02914535).
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in Cohort A (biologic-naive) received filgotinib 200 milligrams (mg) and placebo-to-match (PTM) filgotinib 100 mg orally once daily for 10 weeks.
Drug: Filgotinib · Drug: PTM filgotinib
Participants in Cohort A (biologic-naive) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.
Drug: Filgotinib · Drug: PTM filgotinib
Participants in Cohort A (biologic-naive) received PTM filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.
Drug: PTM filgotinib
Participants in Cohort B (biologic-experienced) received filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.
Drug: Filgotinib · Drug: PTM filgotinib
Participants in Cohort B (biologic-experienced) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.
Drug: Filgotinib · Drug: PTM filgotinib
Participants in Cohort B (biologic-experienced) received PTM filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.
Drug: PTM filgotinib
Participants in the Filgotinib 200 mg arm who completed the Induction Study and achieved either Endoscopy/Bleeding/Stool Frequency (EBS) remission or Mayo Clinic Score (MCS) response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive filgotinib 200 mg and PTM filgotinib 100 mg for an additional 47 weeks (up to Week 58).
Drug: Filgotinib · Drug: PTM filgotinib
Participants in the Filgotinib 200 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive PTM filgotinib orally once daily for an additional 47 weeks (up to Week 58).
Drug: PTM filgotinib
Participants in the Filgotinib 100 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive filgotinib 100 mg and PTM filgotinib 200 mg for an additional 47 weeks (up to Week 58).
Drug: Filgotinib · Drug: PTM filgotinib
Participants in the Filgotinib 100 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were rerandomized at Week 11 into the Maintenance Study to receive PTM filgotinib orally once daily for an additional 47 weeks (up to Week 58).
Drug: PTM filgotinib
Participants in the Placebo arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive PTM filgotinib for an additional 47 weeks (up to Week 58).
Drug: PTM filgotinib
Tablet(s) administered orally once daily
Also known as: GS-6034, GLPG0634
Tablet(s) administered orally once daily
Induction Study: Percentage of Participants Who Achieved Endoscopy/Bleeding/Stool Frequency (EBS) Remission at Week 10
EBS remission was defined as an endoscopic subscore of 0 or 1; rectal bleeding subscore of 0; and at least a 1-point decrease in stool frequency from baseline to achieve a subscore of 0 or 1. Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulceration); rectal bleeding subscore range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes; stool frequency subscore range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal. Total score for EBS ranged from 0 to 9 (sum of all subscores), with higher scores indicating more severe disease.
Time frame: Week 10
Maintenance Study: Percentage of Participants Who Achieved EBS Remission at Week 58
EBS remission was defined as an endoscopic subscore of 0 or 1; rectal bleeding subscore of 0; and at least a 1-point decrease in stool frequency from baseline to achieve a subscore of 0 or 1. Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulceration); rectal bleeding subscore range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes; stool frequency subscore range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal. Total score for EBS ranged from 0 to 9 (sum of all subscores), with higher scores indicating more severe disease.
Time frame: Week 58
Induction Study: Percentage of Participants Who Achieved MCS Remission at Week 10
MCS remission was defined as having a MCS of 2 or less and no single subscore higher than 1. The MCS was composed of subscores from endoscopy (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease \[spontaneous bleeding, ulceration\]), rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), and physician's global assessment (PGA). The PGA acknowledged the participant's daily recollection of abdominal discomfort and general sense of wellbeing, and other observations, such as physical findings and the participant's performance status. The PGA score ranged from 0 to 3 with higher score indicating the severe disease. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating more severe disease.
Time frame: Week 10
Induction Study: Percentage of Participants Who Achieved an Endoscopic Subscore of 0 at Week 10
Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulceration).
Time frame: Week 10
Induction Study: Percentage of Participants Who Achieved Geboes Histologic Remission at Week 10
Geboes histologic remission was assessed using the Geboes histologic scores for evaluation of disease severity in ulcerative colitis and classifies histologic changes. Remission was defined as having Grade 0 of \<= 0.3, Grade 1 of \<= 1.1, Grade 2A of \<= 2A.3, Grade 2B of 2B.0, Grade 3 of 3.0, Grade 4 of 4.0, and Grade 5 of 5.0. Possible scores are Grade 0: Architectural changes (0.0=No abnormality to 0.3=Severe diffuse or multifocal abnormalities); Grade 1: Chronic inflammatory infiltrate (1.0=No increase to 1.3=Marked increase); Grade 2A: Eosinophils in lamina propria (2A.0=No increase to 2A.3-=Marked increase; Grade 2B: Neutrophils in lamina propria (2B.0= No increase to 2B.3=Marked increase); Grade 3: Neutrophils in epithelium (3.0=None to 3.3=\>50% crypts involved); Grade 4: Crypt destruction (4.0=none to 4.3=Unequivocal crypt destruction), and Grade 5: Erosions and ulcerations: (5.0=No erosion, ulceration or granulation to 5.4=Ulcer or granulation tissue).
Time frame: Week 10
Induction Study: Percentage of Participants Who Achieved MCS Remission (Alternative Definition) at Week 10
MCS remission (alternative definition) was defined as having rectal bleeding, stool frequency, and PGA subscores of 0 and an endoscopic subscore of 0 or 1; overall MCS of ≤ 1. MCS possible subscores: rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), PGA subscore (range: 0 to 3 with higher score indicating the severe disease), and an endoscopic subscore (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease \[spontaneous bleeding, ulceration\]. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating more severe disease.
Time frame: Week 10
Induction Study: Pharmacokinetic (PK) Parameter: Cmax of Filgotinib and Its Metabolite GS-829845
Cmax is defined as the maximum observed concentration of drug.
Time frame: Predose and at 0.5, 1, 2, 3, 4 and 6 hours postdose at a single visit between Week 2 and Week 10
Induction Study: PK Parameter: Tmax of Filgotinib and Its Metabolite GS-829845
Tmax is defined as the time to reach maximum observed concentration of drug.
Time frame: Predose and at 0.5, 1, 2, 3, 4 and 6 hours postdose at a single visit between Week 2 and Week 10
Induction Study: PK Parameter: AUCtau of Filgotinib and Its Metabolite GS-82984
AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).
Time frame: Predose and at 0.5, 1, 2, 3, 4 and 6 hours postdose at a single visit between Week 2 and Week 10
Induction Study: PK Parameter: AUClast of Filgotinib and Its Metabolite GS-82984
AUClast is defined as the concentration of drug from time zero to the last observable concentration.
Time frame: Predose and at 0.5, 1, 2, 3, 4 and 6 hours postdose at a single visit between Week 2 and Week 10
Induction Study: PK Parameter: Ctau of Filgotinib and Its Metabolite GS-82984
Ctau is defined as the observed drug concentration at the end of the dosing interval.
Time frame: Predose and at 0.5, 1, 2, 3, 4 and 6 hours postdose at a single visit between Week 2 and Week 10
Maintenance Study: Percentage of Participants Who Achieved MCS Remission at Week 58
MCS remission was defined as having a MCS of 2 or less and no single subscore higher than 1. The MCS was composed of subscores from endoscopy (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease \[spontaneous bleeding, ulceration\]), rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), and PGA. The PGA acknowledged the participant's daily recollection of abdominal discomfort and general sense of wellbeing, and other observations, such as physical findings and the participant's performance status. The PGA score ranged from 0 to 3 with higher score indicating the severe disease. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating more severe disease.
Time frame: Week 58
Maintenance Study: Percentage of Participants Who Achieved Sustained EBS Remission at Week 58
Sustained EBS remission was defined as having achieved EBS remission at both Weeks 10 and 58.
Time frame: Week 58
Maintenance Study: Percentage of Participants Who Achieved 6-Month Corticosteroid-Free EBS Remission at Week 58
Six-month corticosteroid-free EBS remission at Week 58 was defined as achieving EBS remission with no corticosteroid use for the indication of ulcerative colitis for at least 6 months prior to Week 58.
Time frame: Week 58
Maintenance Study: Percentage of Participants Who Achieved Endoscopic Subscore of 0 at Weeks 58
Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulceration).
Time frame: Week 58
Maintenance Study: Percentage of Participants Who Achieved Geboes Histologic Remission at Week 58
Geboes histologic remission was assessed using the Geboes histologic scores for evaluation of disease severity in ulcerative colitis and classifies histologic changes. Remission was defined as having Grade 0 of \<= 0.3, Grade 1 of \<= 1.1, Grade 2A of \<= 2A.3, Grade 2B of 2B.0, Grade 3 of 3.0, Grade 4 of 4.0, and Grade 5 of 5.0. Possible scores are Grade 0: Architectural changes (0.0=No abnormality to 0.3=Severe diffuse or multifocal abnormalities); Grade 1: Chronic inflammatory infiltrate (1.0=No increase to 1.3=Marked increase); Grade 2A: Eosinophils in lamina propria (2A.0=No increase to 2A.3-=Marked increase; Grade 2B: Neutrophils in lamina propria (2B.0= No increase to 2B.3=Marked increase); Grade 3: Neutrophils in epithelium (3.0=None to 3.3=\>50% crypts involved); Grade 4: Crypt destruction (4.0=none to 4.3=Unequivocal crypt destruction), and Grade 5: Erosions and ulcerations: (5.0=No erosion, ulceration or granulation to 5.4=Ulcer or granulation tissue).
Time frame: Week 58
Maintenance Study: Percentage of Participants Who Achieved MCS Remission (Alternative Definition) at Week 58
MCS remission (alternative definition) was defined as having rectal bleeding, stool frequency, and PGA subscores of 0 and an endoscopic subscore of 0 or 1; overall MCS of ≤ 1. MCS possible subscores: rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), PGA subscore (range: 0 to 3 with higher score indicating the severe disease), and an endoscopic subscore (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease \[spontaneous bleeding, ulceration\]. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating more severe disease.
Time frame: Week 58
Maintenance Study: Plasma Concentration of Filgotinib and Its Metabolite GS-829845
Plasma concentration is defined as the measured drug concentration of filgotinib and its metabolite GS-829845. Lower limit of quantitation (LLOQ) was defined as 1 ng/mL for analyte filgotinib and 2 ng/mL for analyte GS-829845.
Time frame: Week 26 (any Time) and Week 58 (predose)
Participants were enrolled at study sites in Australia, New Zealand, North America, South America, Asia and Europe. The first participant was screened on 14 November 2016. The last study visit occurred on 31 March 2020.
| Milestone | Induction Study (Cohort A): Filgotinib 200 mg | Induction Study (Cohort A): Filgotinib 100 mg | Induction Study (Cohort A): Placebo | Induction Study (Cohort B): Filgotinib 200 mg | Induction Study (Cohort B): Filgotinib 100 mg | Induction Study (Cohort B): Placebo | Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg | Maintenance Study: Placebo From Induction Filgotinib 200 mg | Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg | Maintenance Study: Placebo From Induction Filgotinib 100 mg | Maintenance Study: Placebo From Induction Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 245 | 278 | 137 | 262 | 286 | 143 | 0 | 0 | 0 | 0 | 0 |
| Completed | 235 | 256 | 127 | 234 | 262 | 127 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 10 | 22 | 10 | 28 | 24 | 16 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 5 | 6 | 4 | 18 | 14 | 10 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrew consent | 4 | 11 | 4 | 6 | 3 | 3 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 2 | 1 | 3 | 4 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Investigator's discretion | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Did not receive study drug | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Induction Study (Cohort A): Filgotinib 200 mg | Induction Study (Cohort A): Filgotinib 100 mg | Induction Study (Cohort A): Placebo | Induction Study (Cohort B): Filgotinib 200 mg | Induction Study (Cohort B): Filgotinib 100 mg | Induction Study (Cohort B): Placebo | Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg | Maintenance Study: Placebo From Induction Filgotinib 200 mg | Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg | Maintenance Study: Placebo From Induction Filgotinib 100 mg | Maintenance Study: Placebo From Induction Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 202 | 99 | 179 | 91 | 93 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 150 | 41 | 104 | 42 | 64 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 52 | 58 | 75 | 49 | 29 |
| Withdrew: Protocol-specified disease worsening | 0 | 0 | 0 | 0 | 0 | 0 | 34 | 49 | 53 | 39 | 21 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 2 | 10 | 4 | 3 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 5 | 3 | 0 | 1 |
| Withdrew: Withdrew consent | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 1 | 6 | 3 | 4 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Investigator's discretion | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
EBS remission was defined as an endoscopic subscore of 0 or 1; rectal bleeding subscore of 0; and at least a 1-point decrease in stool frequency from baseline to achieve a subscore of 0 or 1. Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulceration); rectal bleeding subscore range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes; stool frequency subscore range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal. Total score for EBS ranged from 0 to 9 (sum of all subscores), with higher scores indicating more severe disease.
| percentage of participants | Induction Study (Cohort A): Filgotinib 200 mg | Induction Study (Cohort A): Filgotinib 100 mg | Induction Study (Cohort A): Placebo | Induction Study (Cohort B): Filgotinib 200 mg | Induction Study (Cohort B): Filgotinib 100 mg | Induction Study (Cohort B): Placebo |
|---|---|---|---|---|---|---|
| Induction Study: Percentage of Participants Who Achieved Endoscopy/Bleeding/Stool Frequency (EBS) Remission at Week 10 | 26.1 (20.4 to 31.8) | 19.1 (14.3 to 23.9) | 15.3 (8.9 to 21.7) | 11.5 (7.4 to 15.5) | 9.5 (5.9 to 13.0) | 4.2 (0.6 to 7.9) |
EBS remission was defined as an endoscopic subscore of 0 or 1; rectal bleeding subscore of 0; and at least a 1-point decrease in stool frequency from baseline to achieve a subscore of 0 or 1. Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulceration); rectal bleeding subscore range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes; stool frequency subscore range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal. Total score for EBS ranged from 0 to 9 (sum of all subscores), with higher scores indicating more severe disease.
| percentage of participants | Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg | Maintenance Study: Placebo From Induction Filgotinib 200 mg | Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg | Maintenance Study: Placebo From Induction Filgotinib 100 mg |
|---|---|---|---|---|
| Maintenance Study: Percentage of Participants Who Achieved EBS Remission at Week 58 | 37.2 (30.2 to 44.2) | 11.2 (4.5 to 18.0) | 23.8 (17.2 to 30.5) | 13.5 (5.8 to 21.1) |
MCS remission was defined as having a MCS of 2 or less and no single subscore higher than 1. The MCS was composed of subscores from endoscopy (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease \[spontaneous bleeding, ulceration\]), rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), and physician's global assessment (PGA). The PGA acknowledged the participant's daily recollection of abdominal discomfort and general sense of wellbeing, and other observations, such as physical findings and the participant's performance status. The PGA score ranged from 0 to 3 with higher score indicating the severe disease. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating more severe disease.
| percentage of participants | Induction Study (Cohort A): Filgotinib 200 mg | Induction Study (Cohort A): Filgotinib 100 mg | Induction Study (Cohort A): Placebo | Induction Study (Cohort B): Filgotinib 200 mg | Induction Study (Cohort B): Filgotinib 100 mg | Induction Study (Cohort B): Placebo |
|---|---|---|---|---|---|---|
| Induction Study: Percentage of Participants Who Achieved MCS Remission at Week 10 | 24.5 (18.9 to 30.1) | 17.0 (12.4 to 21.6) | 12.4 (6.5 to 18.3) | 9.5 (5.8 to 13.3) | 6.0 (3.0 to 8.9) | 4.2 (0.6 to 7.9) |
Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulceration).
| percentage of participants | Induction Study (Cohort A): Filgotinib 200 mg | Induction Study (Cohort A): Filgotinib 100 mg | Induction Study (Cohort A): Placebo | Induction Study (Cohort B): Filgotinib 200 mg | Induction Study (Cohort B): Filgotinib 100 mg | Induction Study (Cohort B): Placebo |
|---|---|---|---|---|---|---|
| Induction Study: Percentage of Participants Who Achieved an Endoscopic Subscore of 0 at Week 10 | 12.2 (7.9 to 16.6) | 5.8 (2.8 to 8.7) | 3.6 (0.1 to 7.2) | 3.4 (1.0 to 5.8) | 2.1 (0.3 to 3.9) | 2.1 (0.0 to 4.8) |
Geboes histologic remission was assessed using the Geboes histologic scores for evaluation of disease severity in ulcerative colitis and classifies histologic changes. Remission was defined as having Grade 0 of \<= 0.3, Grade 1 of \<= 1.1, Grade 2A of \<= 2A.3, Grade 2B of 2B.0, Grade 3 of 3.0, Grade 4 of 4.0, and Grade 5 of 5.0. Possible scores are Grade 0: Architectural changes (0.0=No abnormality to 0.3=Severe diffuse or multifocal abnormalities); Grade 1: Chronic inflammatory infiltrate (1.0=No increase to 1.3=Marked increase); Grade 2A: Eosinophils in lamina propria (2A.0=No increase to 2A.3-=Marked increase; Grade 2B: Neutrophils in lamina propria (2B.0= No increase to 2B.3=Marked increase); Grade 3: Neutrophils in epithelium (3.0=None to 3.3=\>50% crypts involved); Grade 4: Crypt destruction (4.0=none to 4.3=Unequivocal crypt destruction), and Grade 5: Erosions and ulcerations: (5.0=No erosion, ulceration or granulation to 5.4=Ulcer or granulation tissue).
| percentage of participants | Induction Study (Cohort A): Filgotinib 200 mg | Induction Study (Cohort A): Filgotinib 100 mg | Induction Study (Cohort A): Placebo | Induction Study (Cohort B): Filgotinib 200 mg | Induction Study (Cohort B): Filgotinib 100 mg | Induction Study (Cohort B): Placebo |
|---|---|---|---|---|---|---|
| Induction Study: Percentage of Participants Who Achieved Geboes Histologic Remission at Week 10 | 35.1 (28.9 to 41.3) | 23.8 (18.6 to 29.0) | 16.1 (9.5 to 22.6) | 19.8 (14.8 to 24.9) | 13.7 (9.5 to 17.8) | 8.5 (3.5 to 13.4) |
MCS remission (alternative definition) was defined as having rectal bleeding, stool frequency, and PGA subscores of 0 and an endoscopic subscore of 0 or 1; overall MCS of ≤ 1. MCS possible subscores: rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), PGA subscore (range: 0 to 3 with higher score indicating the severe disease), and an endoscopic subscore (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease \[spontaneous bleeding, ulceration\]. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating more severe disease.
| percentage of participants | Induction Study (Cohort A): Filgotinib 200 mg | Induction Study (Cohort A): Filgotinib 100 mg | Induction Study (Cohort A): Placebo | Induction Study (Cohort B): Filgotinib 200 mg | Induction Study (Cohort B): Filgotinib 100 mg | Induction Study (Cohort B): Placebo |
|---|---|---|---|---|---|---|
| Induction Study: Percentage of Participants Who Achieved MCS Remission (Alternative Definition) at Week 10 | 12.2 (7.9 to 16.6) | 8.7 (5.2 to 12.2) | 4.4 (0.6 to 8.2) | 3.8 (1.3 to 6.3) | 2.1 (0.3 to 3.9) | 2.1 (0.0 to 4.8) |
Cmax is defined as the maximum observed concentration of drug.
| nanograms per milliliter (ng/mL) | Induction Study (Cohort A): Filgotinib 200 mg | Induction Study (Cohort A): Filgotinib 100 mg | Induction Study (Cohort B): Filgotinib 200 mg | Induction Study (Cohort B): Filgotinib 100 mg |
|---|---|---|---|---|
| Filgotinib | 1746.3 ± 1244.05 | 725.1 ± 313.36 | 2283.3 ± 1012.03 | 977.9 ± 403.51 |
| Metabolite GS-829845 | 3227.5 ± 1204.50 | 1812.2 ± 701.46 | 4373.3 ± 1121.58 | 2002.9 ± 598.73 |
Tmax is defined as the time to reach maximum observed concentration of drug.
| hour (h) | Induction Study (Cohort A): Filgotinib 200 mg | Induction Study (Cohort A): Filgotinib 100 mg | Induction Study (Cohort B): Filgotinib 200 mg | Induction Study (Cohort B): Filgotinib 100 mg |
|---|---|---|---|---|
| Filgotinib | 1.50 (0.75 to 2.00) | 0.75 (0.50 to 3.00) | 1.00 (0.50 to 2.25) | 0.57 (0.42 to 3.00) |
| Metabolite GS-829845 | 3.76 (2.00 to 4.00) | 3.00 (1.00 to 6.00) | 3.02 (2.13 to 6.00) | 3.00 (1.03 to 6.00) |
AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).
| hour*nanograms per milliliter (h*ng/mL) | Induction Study (Cohort A): Filgotinib 200 mg | Induction Study (Cohort A): Filgotinib 100 mg | Induction Study (Cohort B): Filgotinib 200 mg | Induction Study (Cohort B): Filgotinib 100 mg |
|---|---|---|---|---|
| Filgotinib | 5501.3 ± 1956.39 | 1909.3 ± 788.13 | 6475.6 ± 1643.00 | 2492.3 ± 852.52 |
| Metabolite GS-829845 | 57982.0 ± 17767.52 | 31187.9 ± 11858.78 | 80208.6 ± 25096.57 | 36075.6 ± 13396.86 |
AUClast is defined as the concentration of drug from time zero to the last observable concentration.
| h*ng/mL | Induction Study (Cohort A): Filgotinib 200 mg | Induction Study (Cohort A): Filgotinib 100 mg | Induction Study (Cohort B): Filgotinib 200 mg | Induction Study (Cohort B): Filgotinib 100 mg |
|---|---|---|---|---|
| Filgotinib | 5537.3 ± 1900.93 | 1881.9 ± 797.51 | 6743.1 ± 1743.68 | 2420.3 ± 837.26 |
| Metabolite GS-829845 | 60938.4 ± 6961.77 | 30643.2 ± 12935.37 | 79286.3 ± 27968.49 | 34385.6 ± 15160.15 |
Ctau is defined as the observed drug concentration at the end of the dosing interval.
| ng/mL | Induction Study (Cohort A): Filgotinib 200 mg | Induction Study (Cohort A): Filgotinib 100 mg | Induction Study (Cohort B): Filgotinib 200 mg | Induction Study (Cohort B): Filgotinib 100 mg |
|---|---|---|---|---|
| Filgotinib | 12.0 ± 4.74 | 4.5 ± 3.61 | 36.6 ± 79.06 | 4.1 ± 3.05 |
| Metabolite GS-829845 | 2050.0 ± 493.66 | 934.8 ± 372.68 | 2581.3 ± 777.07 | 1062.8 ± 463.67 |
MCS remission was defined as having a MCS of 2 or less and no single subscore higher than 1. The MCS was composed of subscores from endoscopy (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease \[spontaneous bleeding, ulceration\]), rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), and PGA. The PGA acknowledged the participant's daily recollection of abdominal discomfort and general sense of wellbeing, and other observations, such as physical findings and the participant's performance status. The PGA score ranged from 0 to 3 with higher score indicating the severe disease. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating more severe disease.
| percentage of participants | Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg | Maintenance Study: Placebo From Induction Filgotinib 200 mg | Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg | Maintenance Study: Placebo From Induction Filgotinib 100 mg |
|---|---|---|---|---|
| Maintenance Study: Percentage of Participants Who Achieved MCS Remission at Week 58 | 34.7 (27.8 to 41.5) | 9.2 (3.0 to 15.4) | 22.7 (16.1 to 29.2) | 13.5 (5.8 to 21.1) |
Sustained EBS remission was defined as having achieved EBS remission at both Weeks 10 and 58.
| percentage of participants | Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg | Maintenance Study: Placebo From Induction Filgotinib 200 mg | Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg | Maintenance Study: Placebo From Induction Filgotinib 100 mg |
|---|---|---|---|---|
| Maintenance Study: Percentage of Participants Who Achieved Sustained EBS Remission at Week 58 | 18.1 (12.5 to 23.7) | 5.1 (0.2 to 10.0) | 8.7 (4.2 to 13.2) | 7.9 (1.7 to 14.0) |
Six-month corticosteroid-free EBS remission at Week 58 was defined as achieving EBS remission with no corticosteroid use for the indication of ulcerative colitis for at least 6 months prior to Week 58.
| percentage of participants | Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg | Maintenance Study: Placebo From Induction Filgotinib 200 mg | Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg | Maintenance Study: Placebo From Induction Filgotinib 100 mg |
|---|---|---|---|---|
| Maintenance Study: Percentage of Participants Who Achieved 6-Month Corticosteroid-Free EBS Remission at Week 58 | 27.2 (17.5 to 36.8) | 6.4 (0.0 to 14.4) | 13.6 (5.5 to 21.7) | 5.4 (0.0 to 14.0) |
Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulceration).
| percentage of participants | Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg | Maintenance Study: Placebo From Induction Filgotinib 200 mg | Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg | Maintenance Study: Placebo From Induction Filgotinib 100 mg |
|---|---|---|---|---|
| Maintenance Study: Percentage of Participants Who Achieved Endoscopic Subscore of 0 at Weeks 58 | 15.6 (10.3 to 20.9) | 6.1 (0.9 to 11.4) | 13.4 (8.0 to 18.7) | 7.9 (1.7 to 14.0) |
Geboes histologic remission was assessed using the Geboes histologic scores for evaluation of disease severity in ulcerative colitis and classifies histologic changes. Remission was defined as having Grade 0 of \<= 0.3, Grade 1 of \<= 1.1, Grade 2A of \<= 2A.3, Grade 2B of 2B.0, Grade 3 of 3.0, Grade 4 of 4.0, and Grade 5 of 5.0. Possible scores are Grade 0: Architectural changes (0.0=No abnormality to 0.3=Severe diffuse or multifocal abnormalities); Grade 1: Chronic inflammatory infiltrate (1.0=No increase to 1.3=Marked increase); Grade 2A: Eosinophils in lamina propria (2A.0=No increase to 2A.3-=Marked increase; Grade 2B: Neutrophils in lamina propria (2B.0= No increase to 2B.3=Marked increase); Grade 3: Neutrophils in epithelium (3.0=None to 3.3=\>50% crypts involved); Grade 4: Crypt destruction (4.0=none to 4.3=Unequivocal crypt destruction), and Grade 5: Erosions and ulcerations: (5.0=No erosion, ulceration or granulation to 5.4=Ulcer or granulation tissue).
| percentage of participants | Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg | Maintenance Study: Placebo From Induction Filgotinib 200 mg | Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg | Maintenance Study: Placebo From Induction Filgotinib 100 mg |
|---|---|---|---|---|
| Maintenance Study: Percentage of Participants Who Achieved Geboes Histologic Remission at Week 58 | 38.2 (31.2 to 45.2) | 13.3 (6.0 to 20.5) | 27.9 (20.9 to 34.9) | 18.0 (9.4 to 26.5) |
MCS remission (alternative definition) was defined as having rectal bleeding, stool frequency, and PGA subscores of 0 and an endoscopic subscore of 0 or 1; overall MCS of ≤ 1. MCS possible subscores: rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), PGA subscore (range: 0 to 3 with higher score indicating the severe disease), and an endoscopic subscore (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease \[spontaneous bleeding, ulceration\]. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating more severe disease.
| percentage of participants | Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg | Maintenance Study: Placebo From Induction Filgotinib 200 mg | Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg | Maintenance Study: Placebo From Induction Filgotinib 100 mg |
|---|---|---|---|---|
| Maintenance Study: Percentage of Participants Who Achieved MCS Remission (Alternative Definition) at Week 58 | 22.1 (16.1 to 28.1) | 6.1 (0.9 to 11.4) | 12.2 (7.0 to 17.4) | 7.9 (1.7 to 14.0) |
Plasma concentration is defined as the measured drug concentration of filgotinib and its metabolite GS-829845. Lower limit of quantitation (LLOQ) was defined as 1 ng/mL for analyte filgotinib and 2 ng/mL for analyte GS-829845.
| ng/mL | Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg | Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg |
|---|---|---|
| Filgotinib: Week 26 | 8.5 (5.0 to 25.8) | 4.4 (2.5 to 14.0) |
| Filgotinib: Week 58 | 3.9 (NA to 9.1) | 4.1 (NA to 6.9) |
| Metabolite GS-829845: Week 26 | 2495.0 (1940.0 to 3010.0) | 1180.0 (852.0 to 1550.0) |
| Metabolite GS-829845: Week 58 | 1930.0 (1320.0 to 2630.0) | 973.5 (773.0 to 1350.0) |
Collected over Induction Study: first dose date up to one day before the Maintenance first dose date or last dose date whichever is earlier (maximum 17 weeks) plus 30 days, Maintenance study: First dose to the last dose in the Maintenance Study (maximum 51 weeks) plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Induction Study (Cohort A): Filgotinib 200 mg | 0/245 (0%) | 3/245 (1.2%) | 40/245 (16.3%) |
| Induction Study (Cohort A): Filgotinib 100 mg | 0/278 (0%) | 13/277 (4.7%) | 43/277 (15.5%) |
| Induction Study (Cohort A): Placebo | 0/137 (0%) | 4/137 (2.9%) | 20/137 (14.6%) |
| Induction Study (Cohort B): Filgotinib 200 mg | 0/262 (0%) | 19/262 (7.3%) | 83/262 (31.7%) |
| Induction Study (Cohort B): Filgotinib 100 mg | 0/286 (0%) | 15/285 (5.3%) | 77/285 (27%) |
| Induction Study (Cohort B): Placebo | 0/143 (0%) | 9/142 (6.3%) | 55/142 (38.7%) |
| Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg | 2/202 (1%) | 9/202 (4.5%) | 67/202 (33.2%) |
| Maintenance Study: Placebo From Induction Filgotinib 200 mg | 0/99 (0%) | 0/99 (0%) | 33/99 (33.3%) |
| Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg | 0/179 (0%) | 8/179 (4.5%) | 53/179 (29.6%) |
| Maintenance Study: Placebo From Induction Filgotinib 100 mg | 0/91 (0%) | 7/91 (7.7%) | 33/91 (36.3%) |
| Maintenance Study: Placebo From Induction Placebo | 0/93 (0%) | 4/93 (4.3%) | 26/93 (28%) |
| Event | Induction Study (Cohort A): Filgotinib 200 mg | Induction Study (Cohort A): Filgotinib 100 mg | Induction Study (Cohort A): Placebo | Induction Study (Cohort B): Filgotinib 200 mg | Induction Study (Cohort B): Filgotinib 100 mg | Induction Study (Cohort B): Placebo | Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg | Maintenance Study: Placebo From Induction Filgotinib 200 mg | Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg | Maintenance Study: Placebo From Induction Filgotinib 100 mg | Maintenance Study: Placebo From Induction Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 0/245 | 3/277 | 3/137 | 7/262 | 5/285 | 5/142 | 0/202 | 0/99 | 1/179 | 1/91 | 0/93 |
| AppendicitisInfections and infestations | 0/245 | 1/277 | 0/137 | 0/262 | 0/285 | 0/142 | 1/202 | 0/99 | 2/179 | 0/91 | 0/93 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 0/245 | 1/277 | 0/137 | 1/262 | 0/285 | 0/142 | 0/202 | 0/99 | 0/179 | 1/91 | 0/93 |
| Coronary artery stenosisCardiac disorders | 0/245 | 0/277 | 0/137 | 0/262 | 0/285 | 0/142 | 0/202 | 0/99 | 0/179 | 1/91 | 0/93 |
| Autoimmune hepatitisHepatobiliary disorders | 0/245 | 0/277 | 0/137 | 0/262 | 0/285 | 0/142 | 0/202 | 0/99 | 0/179 | 1/91 | 0/93 |
| Acute hepatitis BInfections and infestations | 0/245 | 0/277 | 0/137 | 0/262 | 0/285 | 0/142 | 0/202 | 0/99 | 0/179 | 1/91 | 0/93 |
| Gastroenteritis viralInfections and infestations | 0/245 | 0/277 | 0/137 | 1/262 | 0/285 | 1/142 | 0/202 | 0/99 | 0/179 | 1/91 | 0/93 |
| Meniscus injuryInjury, poisoning and procedural complications | 0/245 | 0/277 | 0/137 | 0/262 | 0/285 | 0/142 | 0/202 | 0/99 | 0/179 | 1/91 | 0/93 |
| Dental cystGastrointestinal disorders | 0/245 | 0/277 | 0/137 | 0/262 | 0/285 | 0/142 | 0/202 | 0/99 | 0/179 | 0/91 | 1/93 |
| Supernumerary teethGastrointestinal disorders | 0/245 | 0/277 | 0/137 | 0/262 | 0/285 | 0/142 | 0/202 | 0/99 | 0/179 | 0/91 | 1/93 |
| Event | Induction Study (Cohort A): Filgotinib 200 mg | Induction Study (Cohort A): Filgotinib 100 mg | Induction Study (Cohort A): Placebo | Induction Study (Cohort B): Filgotinib 200 mg | Induction Study (Cohort B): Filgotinib 100 mg | Induction Study (Cohort B): Placebo | Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg | Maintenance Study: Placebo From Induction Filgotinib 200 mg | Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg | Maintenance Study: Placebo From Induction Filgotinib 100 mg | Maintenance Study: Placebo From Induction Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 6/245 | 3/277 | 5/137 | 14/262 | 11/285 | 6/142 | 21/202 | 18/99 | 18/179 | 16/91 | 10/93 |
| NasopharyngitisInfections and infestations | 7/245 | 9/277 | 2/137 | 20/262 | 20/285 | 11/142 | 22/202 | 6/99 | 12/179 | 6/91 | 5/93 |
| HeadacheNervous system disorders | 11/245 | 12/277 | 6/137 | 19/262 | 10/285 | 9/142 | 7/202 | 0/99 | 10/179 | 5/91 | 5/93 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/245 | 4/277 | 2/137 | 8/262 | 10/285 | 7/142 | 8/202 | 7/99 | 6/179 | 3/91 | 4/93 |
| AnaemiaBlood and lymphatic system disorders | 6/245 | 10/277 | 4/137 | 12/262 | 11/285 | 10/142 | 4/202 | 0/99 | 4/179 | 1/91 | 0/93 |
| Abdominal painGastrointestinal disorders | 3/245 | 3/277 | 3/137 | 8/262 | 7/285 | 9/142 | 8/202 | 6/99 | 6/179 | 2/91 | 4/93 |
| PyrexiaGeneral disorders | 5/245 | 1/277 | 1/137 | 6/262 | 3/285 | 8/142 | 6/202 | 1/99 | 4/179 | 3/91 | 1/93 |
| Upper respiratory tract infectionInfections and infestations | 2/245 | 2/277 | 0/137 | 13/262 | 4/285 | 5/142 | 11/202 | 3/99 | 6/179 | 3/91 | 3/93 |
| NauseaGastrointestinal disorders | 8/245 | 3/277 | 1/137 | 7/262 | 15/285 | 6/142 | 5/202 | 1/99 | 4/179 | 0/91 | 2/93 |
Safety Analysis Set for the Induction Study (Cohorts A and B) included all participants who took at least 1 dose of study drug in the Induction Study.
| Age, Categorical(Participants) | Induction Study (Cohort A): Filgotinib 200 mg | Induction Study (Cohort A): Filgotinib 100 mg | Induction Study (Cohort A): Placebo | Induction Study (Cohort B): Filgotinib 200 mg | Induction Study (Cohort B): Filgotinib 100 mg | Induction Study (Cohort B): Placebo | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 234 | 261 | 129 | 243 | 264 | 128 | 1259 |
| >=65 years | 11 | 16 | 8 | 19 | 21 | 14 | 89 |
| Sex: Female, Male(Participants) | Induction Study (Cohort A): Filgotinib 200 mg | Induction Study (Cohort A): Filgotinib 100 mg | Induction Study (Cohort A): Placebo | Induction Study (Cohort B): Filgotinib 200 mg | Induction Study (Cohort B): Filgotinib 100 mg | Induction Study (Cohort B): Placebo | Total |
|---|---|---|---|---|---|---|---|
| Female | 122 | 120 | 50 | 114 | 99 | 56 | 561 |
| Male | 123 | 157 | 87 | 148 | 186 | 86 | 787 |
| Race/Ethnicity, Customized(Participants) | Induction Study (Cohort A): Filgotinib 200 mg | Induction Study (Cohort A): Filgotinib 100 mg | Induction Study (Cohort A): Placebo | Induction Study (Cohort B): Filgotinib 200 mg | Induction Study (Cohort B): Filgotinib 100 mg | Induction Study (Cohort B): Placebo | Total |
|---|---|---|---|---|---|---|---|
| Race — American Indian or Alaska Native | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Race — Asian | 77 | 79 | 38 | 50 | 51 | 27 | 322 |
| Race — Black or African American | 2 | 3 | 1 | 4 | 6 | 3 | 19 |
| Race — White | 165 | 192 | 95 | 190 | 212 | 98 | 952 |
| Race — Other | 0 | 2 | 2 | 0 | 0 | 1 | 5 |
| Race — Not Permitted | 0 | 1 | 1 | 18 | 16 | 13 | 49 |
| Race/Ethnicity, Customized(Participants) | Induction Study (Cohort A): Filgotinib 200 mg | Induction Study (Cohort A): Filgotinib 100 mg | Induction Study (Cohort A): Placebo | Induction Study (Cohort B): Filgotinib 200 mg | Induction Study (Cohort B): Filgotinib 100 mg | Induction Study (Cohort B): Placebo | Total |
|---|---|---|---|---|---|---|---|
| Ethnicity — Not Hispanic or Latino | 238 | 269 | 134 | 249 | 273 | 134 | 1297 |
| Ethnicity — Hispanic or Latino | 6 | 6 | 3 | 8 | 8 | 4 | 35 |
| Ethnicity — Not Permitted | 1 | 2 | 0 | 5 | 4 | 4 | 16 |
| Region of Enrollment(Participants) | Induction Study (Cohort A): Filgotinib 200 mg | Induction Study (Cohort A): Filgotinib 100 mg | Induction Study (Cohort A): Placebo | Induction Study (Cohort B): Filgotinib 200 mg | Induction Study (Cohort B): Filgotinib 100 mg | Induction Study (Cohort B): Placebo | Total |
|---|---|---|---|---|---|---|---|
| Poland | 57 | 56 | 25 | 17 | 22 | 11 | 188 |
| United States | 14 | 33 | 19 | 36 | 58 | 21 | 181 |
| India | 55 | 49 | 27 | 8 | 3 | 3 | 145 |
| Japan | 15 | 16 | 6 | 29 | 29 | 14 | 109 |
| Ukraine | 33 | 46 | 24 | 1 | 2 | 0 | 106 |
| France | 1 | 1 | 1 | 32 | 26 | 19 | 80 |
| Germany | 1 | 3 | 0 | 31 | 26 | 9 | 70 |
| Russia | 21 | 10 | 12 | 6 | 9 | 1 | 59 |
| Italy | 4 | 6 | 1 | 15 | 19 | 12 | 57 |
| United Kingdom | 7 | 3 | 0 | 12 | 11 | 7 | 40 |
| Belgium | 0 | 0 | 0 | 16 | 14 | 6 | 36 |
| South Korea | 1 | 7 | 2 | 5 | 12 | 5 | 32 |
| Australia | 6 | 3 | 1 | 10 | 8 | 2 | 30 |
| Hungary | 9 | 8 | 3 | 0 | 5 | 2 | 27 |
| Romania | 3 | 3 | 2 | 3 | 5 | 3 | 19 |
| Switzerland | 0 | 0 | 0 | 7 | 5 | 7 | 19 |
| Canada | 2 | 2 | 1 | 3 | 5 | 4 | 17 |
| Czechia | 3 | 4 | 4 | 4 | 2 | 0 | 17 |
| Taiwan | 1 | 3 | 0 | 4 | 4 | 0 | 12 |
| Israel | 1 | 1 | 0 | 5 | 4 | 0 | 11 |
| New Zealand | 1 | 2 | 0 | 4 | 2 | 1 | 10 |
| South Africa | 0 | 3 | 2 | 2 | 1 | 0 | 8 |
| Spain | 0 | 1 | 0 | 1 | 4 | 2 | 8 |
| Austria | 0 | 0 | 0 | 3 | 2 | 2 | 7 |
| Croatia | 0 | 1 | 0 | 2 | 1 | 2 | 6 |
| Norway | 0 | 2 | 2 | 1 | 1 | 0 | 6 |
| Sweden | 0 | 0 | 1 | 1 | 1 | 3 | 6 |
| Bulgaria | 1 | 3 | 1 | 0 | 0 | 0 | 5 |
| Greece | 1 | 1 | 0 | 0 | 2 | 1 | 5 |
| Georgia | 1 | 2 | 1 | 0 | 0 | 0 | 4 |
| Hong Kong | 2 | 1 | 0 | 1 | 0 | 0 | 4 |
| Netherlands | 0 | 0 | 0 | 2 | 0 | 2 | 4 |
| Serbia | 1 | 2 | 1 | 0 | 0 | 0 | 4 |
| Slovakia | 2 | 0 | 0 | 0 | 0 | 2 | 4 |
| Argentina | 1 | 1 | 0 | 1 | 0 | 0 | 3 |
| Malaysia | 0 | 2 | 1 | 0 | 0 | 0 | 3 |
| Ireland | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
| Portugal | 0 | 1 | 0 | 0 | 1 | 0 | 2 |
| Mexico | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Singapore | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
Showing the first 100 of 343 sites across 40 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2016 to primary completion in Mar 2020, 40 months.
Results were first posted in Apr 2021, 1 year after primary completion.
Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 40 months is below that.
Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GLPG0634